Pfizer-BioNTech vaccine not troubled by variants so far, says CEO - Action News
Home WebMail Tuesday, November 26, 2024, 06:05 AM | Calgary | -17.5°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Politics

Pfizer-BioNTech vaccine not troubled by variants so far, says CEO

One of the peoplebehind the Pfizer-BioNTech COVID-19 vaccine says he has yet to see any evidence that emerging variants of the disease have found a way to defeat it.

'So far, the data is really encouraging for all types of variants,' said BioNTech co-founder Dr. Ugur Sahin

Exclusive interview with BioNTech CEO and co-founder

3 years ago
Duration 9:23
In his first Canadian interview and exclusive with Power & Politics, BioNTech CEO and co-founder Dr. Uur ahin says he anticipates and is confident that the vaccine will be approved for younger children - and explains why he is not worried about variants that will appear in the future.

One of the peoplebehind the Pfizer-BioNTech COVID-19 vaccine says he has yet to see any evidence that emerging variants of the disease have found a way to defeat it.

Dr. Ugur Sahin, who founded BioNTech with his wife Dr. zlem Treci, told CBC News Network's Power & Politics today that scientists have two main concerns when it comes to variants of the COVID-19 virus.

"One concern is that some variants just have a higher infectivity and therefore it's more difficult to control the pandemic," Sahin told guest host David Common. "The second concern is that variants potentially could escape existing immune responses."

To address the second concern,BioNTech's team of researchers run tests on the vaccine's effectiveness against individual variants.

"So far, the data is really encouraging for all types of variants," he said. "We do not have any evidence that our vaccine would not work against any of the prevalent variants."

While Sahin said he is confident his vaccine will deal with existing variants, he said his company is constantly monitoring its effectiveness on new variants "to be on the safe side."

BioNTechis also researchingpossible risks the Pfizer-BioNTech vaccine might present topregnant women.

Sahin said that pregnant women have participated in vaccine trials "mainly"women in the third trimester.

Limited data on pregnancy impacts

"There is no indication for increased risk of death. But we have to see that this data is still early data," he said. "And therefore, any decision for taking the vaccine should be aligned with the physician based on an analysis of risk-benefit."

As concerns about the risk of bloodclots associated with theAstraZeneca-Oxford vaccine have grown, many have asked whether thosewho have had a single shot of the AstraZeneca-Oxford productcan take the Pfizer-BioNTech vaccine as their second shot.

Sahin said his company does not have data to suggest mixing vaccines is safe but there is evidence that patients with antibodies resultingfrom aCOVID-19 infectionget better protection once they take the Pfizer-BioNTech shot.

Dr. Ugur Sahin and Dr. zlem Treci, the husband-and-wife founders of the coronavirus vaccine developer BioNTech, pose for a photo at an Axel Springer Award ceremony in March. (Associated Press/Bernd von Jutrczenka)

"The decision at the end of the day is a decision of the health institutions," he said.

Asked about the impact his vaccine is having on the global pandemic, Sahin saidit's a "fantastic feeling" to know he is helping so many people.

"We see the impact of our vaccine," he said. "We feel that this is a privilege, that as a scientist, we have accomplished something which is of benefit for mankind and benefit for our people."

You can watch full episodes of Power & Politics on CBC Gem, the CBC's streaming service.

Add some good to your morning and evening.

Your daily guide to the coronavirus outbreak. Get the latest news, tips on prevention and your coronavirus questions answered every evening.

...

The next issue of the Coronavirus Brief will soon be in your inbox.

Discover all CBC newsletters in theSubscription Centre.opens new window

This site is protected by reCAPTCHA and the Google Privacy Policy and Google Terms of Service apply.